The Latest
-
China competition
Drugs from China are reshaping biotech. Track the licensing deals here.
U.S. and European drugmakers have already signed more licensing deals with their China-based counterparts in 2026 than they did in all of 2025, according to BioPharma Dive data.
Updated 5 hours ago -
Sponsored by PAXXUS
Completing the circle: the next evolution in sustainable pharmaceutical blister packaging
Discover how innovative PET and PP lidding are advancing sustainable pharmaceutical blister packaging.
-
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
-
News roundup
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
-
Emerging biotech
AI drugmaker Isomorphic restocks with $5B fundraise
Even as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.
-
Deep Dive
Biotech M&A is accelerating. Track the deals that are happening here.
Lilly and Johnson & Johnson on Monday added to a run of private company acquisitions that has accounted for the majority of the sector’s dealmaking activity in 2026.
Updated Nov. 16, 2026 -
Startup launches
Marrow sets out to challenge genetic medicines for severe blood diseases
Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta thalassemia.
-
Roche breast cancer pill cleared by FDA
Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.
Updated Nov. 17, 2026 -
CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
-
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
Lilly’s 15th announced acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.
-
J&J bets $2.2B on Ollin’s vision loss drug
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
-
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
-
This week in charts
This week in charts: Brain drugs are back on venture capitalists’ minds
Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.
-
Emerging biotech
One of Europe’s leading VCs banks a €725M ‘crossover’ fund
Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.
-
Big-name investors pour $100M into DNA therapeutics developer Seawolf
The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.
-
Deep Dive // Emerging biotech
Biotech startups are built on venture capital. Track funding rounds here.
At least four neuroscience-focused biotechs have raised venture fundings since late October, matching the total number of rounds raised by brain drug developers over the previous six months, according to BioPharma Dive data.
Updated Nov. 12, 2026 -
IPO window
Windward prices $175M IPO to advance China-licensed lung drugs
The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
-
News roundup
Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.
-
China competition
BIO unveils plan for US to remain biotech’s ‘global leader’
A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.
-
Obesity drugs
Blackstone bets $1.5B on Pfizer’s obesity drug
The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
-
Bristol Myers research chief to depart in ‘evolution’ of company’s structure
Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.
-
Drug price hikes in Germany could push US costs higher, study says
The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.
-
Trump administration
The FDA has over 1k open jobs — and the staffing shortage is hitting pharma
The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.
-
News roundup
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
-
Gene editing
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
-
PepGen soars on promising early data for muscular dystrophy drug
While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.